Carl Borrebaeck has a DSc in biochemistry with a focus on molecular immunology, and is professor at Lund University. Carl Borrebaeck is a successful entrepreneur who contributed to the start of several new life science companies, including Alligator BioScience AB, BioInvent International AB and Immunovia AB. BioInvent was awarded the prestigious Scrip‘s Licensing Deal of the Year in 2009 and Immunovia received the 2016 "Stars of Innovation Prize". Carl Borrebaeck received AkzoNobel’s Science Prize in 2009, the Royal Academy of Engineering Science’s gold medal for ground-breaking cancer biomarker research in 2012, Research!Sweden Prize for medical research in 2012 and the BiotechBuilder award in 2017, for outstanding entrepreneurial achievements. Carl Borrebaeck is Director of CREATE Health - the Strategic Centre for Translational Cancer Research, and former Vice President of Lund University, responsible for its innovation system. He is the founding mentor for Nordic Mentor Network for Entrepreneurship (NOME) in Sweden.
Current appointments: Carl Borrebaeck is Chairman of Immunovia AB and CB Ocean Capital AB, board member of Alligator Bioscience AB, Clinical Laserthermia Systems AB, Scandion AS and partner in Immunova HB.
Previous appointments (last five years): Board member of Atlas Therapeutics AB, BioInvent International AB, LU Holding AB, Medicon Village AB and Wntresearch AB. Deputy board member of Ideon Center AB and Endo Medical AB.
Professor Ian Kimber holds a Bachelor‘s degree in biology and a Master’s degree in immunology, a subject in which he also has a PhD. Professor Kimber is at the time of publication Professor of Toxicology at the Faculty of Biology, Medicine and Health at the University of Manchester. Professor Kimber has extensive research experience, and his previous work includes cancer research at Paterson Laboratories for Cancer Research, Head of Division at ICI and Zeneca, with a focus on immunology as well as cell and molecular biology, Head of Division at AstraZeneca in toxicology research and global responsibility for toxicology research at Syngenta. Professor Kimber is and has been a member of several professional and academic associations and has been awarded several awards and distinctions for his research, including OBE (Officer of the Order of the British Empire in the Queen’s Birthday Honours List in 2011 for Services to Science). Ian Kimber developed LLNA (Local Lymph Node Assay) and has written over 550 articles, 100 book chapters and six books on toxicology and immunology research.
Current appointments: Professor Ian Kimber is a member of the board at Kimber Biomedical Ltd and Sea Court Management Company.
Previous appointments (last five years): None.
Carl-Henric Nilsson has a wide-ranging academic background and holds a PhD in industrial management and an MSc in mechanical engineering from Lund University. Carl-Henric Nilsson also holds a Bachelor‘s degree in Business Administration from Lund University. Carl-Henric Nilsson has more than ten years of experience on the board of various companies, including Finqr AB, Scandify and Danske Bank Lund. His studies have been rewarded with, among other distinctions, the prize awarded in 1988 by SAF and the Southern Swedish Chamber of Commerce for best Master’s thesis, and within his professional field Carl-Henric Nilsson has several international academic appointments.
Current appointments: Carl-Henric Nilsson is Chairman of Boffins Broadcast AB, Boffins Holding AB, Finqr AB and Linton & Wahlgren AB. Board member of Ecobränsle in Karlshamn AB, FX International AB, Kunskapspartner i Lund Holding AB and Scandify AB. Board member and CEO of Kunskapspartner i Lund AB and PJA Fastighets AB as well as Chairman of the Board and CEO of Smash&Grab Fastigheter AB. Deputy member of the board at Helhjärtad Finans AB, Stelpan AB and Vinur AB. Owner of Acme Incorporated, Technology Management Consulting in Lund and Örestads Gravyr.
Previous appointments (last five years): Carl-Henric Nilsson was a member of the Advisory Board at Danske Bank Lund.
Ann Gidner holds an MSc from Lund University with a focus on chemical engineering and bioprocessing. Ann Gidner was awarded a scholarship to specialize in bioprocessing at the Ecole National Supérieure d‘Ingénieurs de Génie Chimique in Toulouse, France, and has a Bachelor’s degree in Business Administration from Lund University. Ann Gidner has extensive experience of senior positions in pharmaceutical and medical technology, where she previously worked as Managing Director of Monocl AB and Life Science Director at Semcon Caran AB. Ann Gidner also has many years’ experience of global responsibility for business development, sales and marketing in major international Contract Pharma groups, such as Cambrex Corporation, based in New Jersey, USA and Saltigo GmbH, based in Germany. In addition, Ann Gidner has held several positions in other companies with a particular focus on business development and portfolio management.
Current appointments: Ann Gidner holds a senior position at Albumedix A/S, which is part of the Novozymes Group.
Previous appointments (last five years): Ann Gidner was formerly Managing Director and Partner in Monocl AB and held a senior position at Semcon AB.
Laura Chirica holds a BSc in biotechnology from the University of Bucharest, Romania, as well as an MSc in biochemistry from Middle East Technical University, Turkey. In addition, Laura Chirica holds a PhD in Medical Biochemistry from Umeå University. Laura Chirica has extensive experience in designing and implementing sales, marketing and commercialization strategies in pharmaceutical and medical technology companies and works at the time of publication as Chief Commercial Officer at Immunovia AB with responsibility for the company’s global commercialization strategies. Previous experience has included employment at Euro Diagnostica AB, Sartorius Stedin Biotech and Dako A/S.
Current appointments: Laura Chirica is Chief Commercial Officer at Immunovia AB.
Previous appointments (last five years): Management position at Euro Diagnostica AB.